VERU Veru, Inc.
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
Company profile
Ticker
VERU
Exchange
Website
CEO
Mitchell Shuster Steiner
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Female Health Co
SEC CIK
Corporate docs
IRS number
391144397
VERU stock data
()
Investment data
Securities sold
Number of investors
Calendar
8 Aug 19
11 Dec 19
30 Sep 20
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 9.73M | 6.98M | 6.37M | 5.2M | |
| Net income | -2.77M | -4.03M | -2.15M | -7.92M | |
| Diluted EPS | -0.04 | -0.06 | -0.03 | -0.14 | |
| Net profit margin | -28.52% | -57.83% | -33.72% | -152% | |
| Operating income | -1.84M | -2.12M | -1.01M | -3.77M | |
| Net change in cash | 2.14M | -3.08M | 5.22M | -1.82M | |
| Cash on hand | 8.04M | 5.9M | 8.98M | 3.76M | |
| Cost of revenue | 3.16M | 2.37M | 1.73M | 2.01M |
| Annual (USD) | Sep 18 | Sep 17 | Sep 16 | Sep 15 | |
|---|---|---|---|---|---|
| Revenue | 15.86M | 13.66M | 22.13M | 32.6M | |
| Net income | -23.94M | -6.61M | 344.73K | 4.35M | |
| Diluted EPS | -0.44 | -0.25 | 0.01 | 0.15 | |
| Net profit margin | -151% | -48.42% | 1.56% | 13.33% | |
| Operating income | -20.87M | -8.49M | 3.02M | 6.62M | |
| Net change in cash | 481.91K | 892.52K | -1.72M | -1.69M | |
| Cash on hand | 3.76M | 3.28M | 2.39M | 4.11M | |
| Cost of revenue | 7.08M | 6.64M | 8.78M | 13.63M |
Financial data from Veru earnings reports
Financial report summary
?Management Discussion
- The Company generated net revenues of $9.7 million and net loss of $2.8 million, or $(0.04) per basic and diluted common share, for the three months ended June 30, 2019, compared to net revenues of $5.5 million and net loss of $7.9 million, or $(0.15) per basic and diluted common share, for the three months ended June 30, 2018. Net revenues increased 77% for the period.
- FC2 net revenues represented 95% of total net revenues. FC2 net revenues increased 69% for the period. There was a 9% increase in total FC2 unit sales and an increase in FC2 average sales price per unit of 56%. The increase in the FC2 average sales price per unit compared to the same period last year was due to the increase in sales in the U.S. prescription channel. The Company experienced an increase in FC2 net revenues of 1,074% in the U.S. prescription channel and a slight decrease in global public sector net revenues of 4%.
- Cost of sales increased to $3.2 million in the three months ended June 30, 2019 from $2.4 million for the same period last year primarily due to the increase in unit sales in the U.S. prescription channel.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
Financial reports
10-Q
2019 Q3
Quarterly report
8 Aug 19
10-Q
2019 Q2
Quarterly report
15 May 19
10-Q
2019 Q1
Quarterly report
13 Feb 19
10-K
2018 FY
Annual report
13 Dec 18
10-Q
2018 Q3
Quarterly report
14 Aug 18
10-Q
2018 Q2
Quarterly report
11 May 18
10-Q
2018 Q1
Quarterly report
14 Feb 18
10-K/A
2017 FY
Annual report (amended)
5 Jan 18
10-K
2017 FY
Annual report
2 Jan 18
10-Q
2017 Q3
Quarterly report
9 Aug 17
Current reports
8-K
Results of Operations and Financial Condition
8 Aug 19
8-K
Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results
15 May 19
8-K
Departure of Directors or Certain Officers
29 Mar 19
8-K
Veru Reports Strong Fiscal 2019 First Quarter Financial Results
13 Feb 19
8-K
Other Events
20 Dec 18
8-K
Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter
13 Dec 18
8-K
Veru Announces Proposed Public Offering of Common Stock
27 Sep 18
8-K
Veru Reports Fiscal 2018 Third Quarter Financial Results
14 Aug 18
8-K
Departure of Directors or Certain Officers
1 Jun 18
8-K
Veru Reports Fiscal 2018 Second-Quarter Financial Results
9 May 18
Registration and prospectus
S-8
Registration of securities for employees
15 May 19
S-8
Registration of securities for employees
13 Dec 18
424B5
Prospectus supplement for primary offering
27 Sep 18
424B5
Prospectus supplement for primary offering
26 Sep 18
S-8
Registration of securities for employees
11 Jan 18
424B5
Prospectus supplement for primary offering
29 Dec 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Dec 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Dec 17
S-3
Shelf registration
25 Oct 17
D
$22.68M in equity, sold $22.68M, 23 investors
9 Nov 16
Proxies
DEFA14A
Additional proxy soliciting materials
28 Jan 19
DEF 14A
Definitive proxy
28 Jan 19
PRE 14A
Preliminary proxy
14 Dec 18
DEF 14A
Definitive proxy
26 Jan 18
DEFA14A
Additional proxy soliciting materials
26 Jan 18
DEFA14A
Additional proxy soliciting materials
25 Jul 17
DEFA14A
Additional proxy soliciting materials
17 Jul 17
DEFA14A
Additional proxy soliciting materials
14 Jul 17
DEF 14A
Definitive proxy
21 Jun 17
PRE 14A
Preliminary proxy
19 May 17
Other
EFFECT
Notice of effectiveness
14 Nov 17
UPLOAD
Letter from SEC
5 Aug 16
CORRESP
Correspondence with SEC
18 Jul 16
UPLOAD
Letter from SEC
11 Jul 16
CORRESP
Correspondence with SEC
21 Jun 16
UPLOAD
Letter from SEC
14 Jun 16
NO ACT
No action letter
4 Dec 15
UPLOAD
Letter from SEC
3 Sep 15
CORRESP
Correspondence with SEC
1 Sep 15
UPLOAD
Letter from SEC
20 Aug 15
Ownership
SC 13D/A
Veru Inc.
2 Aug 17
SC 13D/A
Veru Inc.
2 Aug 17
SC 13G
Female Health Co
23 May 17
SC 13D
Female Health Co
7 Nov 16
SC 13D
Female Health Co
7 Nov 16
SC 13G/A
Female Health Co
10 Mar 16
SC 13G/A
Female Health Co
16 Feb 16
SC 13G/A
Female Health Co
17 Feb 15
SC 13G/A
Female Health Co
17 Feb 15
SC 13G
Female Health Co
10 Jul 14